PhD in Biochemistry and Molecular Biology and have been working in the field of antibody and novel molecule development using phage display for 10 years. In 2019, I founded the startup KRABS Biotechnology, which focuses on developing new antibodies for human and animal health, as well as for various biotechnological applications. I have served as CEO since the company's inception, overseeing public funding, investment, client acquisition, and partnership development. I also coordinated and directly participated in the development of our first drug: a topical treatment based on a novel monoclonal antibody (mAb) targeting the kallikrein 7 enzyme, which has since been granted a US patent (US12590170B2) and is under review in Brazil and Europe. Reach me at: marcelo@krabsbiotec.com.br